相似化合物
130345-50-5 6924-72-7 23088-24-6欧盟法规
ECHA物质C&L通报上下游产品
CAS号619-05-6 3,4-二氨基苯甲酸 | CAS号23088-23-5 6-喹喔啉羧酸甲酯 | CAS号107-83-5 异己烷 | CAS号517-21-5 乙二醛亚硫酸氢钠水合物 | CAS号6924-72-7 乙基喹噁啉-6-羧酸 | CAS号37466-90-3 3,4-二氨基苯甲酸乙酯 | CAS号488834-75-9 (喹噁啉-6-基)甲醇 | CAS号130345-50-5 6-喹喔啉甲醛 | CAS号258503-93-4 喹喔啉-6-羰基氯合成工艺路线路线简述
- 合成目标产物 6-Quinoxalinecarboxylic Acid 主要起始原料 Methyl 6-Quinoxalinecarboxylate
- (文献来源)合成步骤主要原料 Methyl 6-Quinoxalinecarboxylate
3,4-二氨基苯甲酸乙酯置于氢氧化钾,水,Glyoxal Sodium Bisulfite体系中,化学反应生成 6-喹喔啉羧酸
参考文献:Birkofer; Widmann,Chemische Berichte,1953,Vol. 86,P. 1295,1301
标题:Birkofer; Widmann,Chemische Berichte,1953,Vol. 86,P. 1295,1301
海关参考信息
- 2905110000-甲醇
2906210000-苄醇
2912110000-甲醛
2912210000-苯甲醛 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2003092064-A1
优先权日:2001-04-05
标题 :System for the synthesis of spatially separated libraries of compounds and methods for the use thereof
发明人:READER JOHN C
权利人:MILLENNIUM PHARM INC
摘要:Featured is an apparatus useful for preparing combinatorial libraries of compounds in a parallel fashion so that the individual compounds of the library are spatially separate and the position of each compound of the library in the apparatus is known. Moreover, the apparatus is useful for the preparation of combinatorial libraries of compounds where the library is constructed from three or more building blocks, e.g., three, four, five, six or seven building blocks, resulting in a three, four, five, six or seven dimensional combinatorial library. Also featured are related methods for the preparation of three, four, five, six or seven dimensional combinatorial libraries of compounds using the apparatus of the present invention.
专利号:WO-9845272-A1
优先权日:1997-04-07
标题:Topoisomerase inhibitors
发明人:DEADY LESLIE WILLIAM; DENNY WILLIAM ALEXANDER; KAYE ANTHONY JAMES
权利人:UNIV LATROBE; DEADY LESLIE WILLIAM; DENNY WILLIAM ALEXANDER; KAYE ANTHONY JAMES
摘要:The invention provides a novel series of tetracyclic quinoline and quinoxaline carboxamides, bis compounds in which two of the tetracyclic compounds are joined by a linker, and pharmaceutically-acceptable salts and N-oxides thereof, which have the ability to inhibit topoisomerase activity. The compounds are active in vitro and in vivo against tumour cells. Methods of synthesis and pharmaceutical compositions are also claimed.